A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

97

Participants

Timeline

Start Date

June 3, 2022

Primary Completion Date

September 10, 2024

Study Completion Date

September 10, 2024

Conditions
Essential Tremor
Interventions
DRUG

SAGE-324

SAGE-324 oral tablets

Trial Locations (38)

10003

Sage Investigational Site, New York

10032

Sage Investigational Site, New York

12039

Sage Investigational Site, Kirkland

22042

Sage Investigational Site, West Falls Church

28806

Sage Investigational Site, Asheville

30030

Sage Investigational Site, Decatur

30329

Sage Investigational Site, Atlanta

32803

Sage Investigational Site, Orlando

33024

Sage Investigational Site, Hollywood

33067

Sage Investigational Site, Coral Springs

33136

Sage Investigational Site, Miami

33175

Sage Investigational Site, Miami

33176

Sage Investigational Site, Miami

33486

Sage Investigational Site, Boca Raton

33612

Sage Investigational Site, Tampa

34105

Sage Investigational Site, Naples

34205

Sage Investigational Site, Bradenton

35244

Sage Investigational Site, Hoover

38157

Sage Investigational Site, Memphis

40509

Sage Investigational Site, Lexington

45219

Sage Investigational Site, Cincinnati

45417

Sage Investigational Site, Dayton

48334

Sage Investigational Site, Farmington Hills

66160

Sage Investigational Site, Kansas City

71105

Sage Investigational Site, Shreveport

74136

Sage Investigational Site, Tulsa

76104

Sage Investigational Site, Fort Worth

77030

Sage Investigational Site, Houston

77450

Sage Investigational Site, Katy

78681

Sage Investigational Site, Round Rock

78746

Sage Investigational Site, Austin

80113

Sage Investigational Site, Englewood

85258

Sage Investigational Site, Scottsdale

90095

Sage Investigational Site, Los Angeles

92708

Sage Investigational Site, Fountain Valley

92835

Sage Investigational Site, Fullerton

99202

Sage Investigational Site, Spokane

02131

Sage Investigational Site, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sage Therapeutics

INDUSTRY

NCT05366751 - A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor | Biotech Hunter | Biotech Hunter